From cardiovascular system to brain, the potential protective role of Mas Receptors in COVID-19 infection.


Journal

European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354

Informations de publication

Date de publication:
15 Nov 2023
Historique:
received: 13 07 2023
revised: 15 09 2023
accepted: 18 09 2023
medline: 27 10 2023
pubmed: 30 9 2023
entrez: 29 9 2023
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) has been declared a new pandemic in March 2020. Although most patients are asymptomatic, those with underlying cardiovascular comorbidities may develop a more severe systemic infection which is often associated with fatal pneumonia. Nonetheless, neurological and cardiovascular manifestations could be present even without respiratory symptoms. To date, no COVID-19-specific drugs are able for preventing or treating the infection and generally, the symptoms are relieved with general anti-inflammatory drugs. Angiotensin-converting-enzyme 2 (ACE2) may function as the receptor for virus entry within the cells favoring the progression of infection in the organism. On the other hand, ACE2 is a relevant enzyme in renin angiotensin system (RAS) cascade fostering Ang1-7/Mas receptor activation which promotes protective effects in neurological and cardiovascular systems. It is known that RAS is composed by two functional countervailing axes the ACE/AngII/AT1 receptor and the ACE/AngII/AT2 receptor which counteracts the actions mediated by AngII/AT1 receptor by inducing anti-inflammatory, antioxidant and anti-growth functions. Subsequently an "alternative" ACE2/Ang1-7/Mas receptor axis has been described with functions similar to the latter protective arm. Here, we discuss the neurological and cardiovascular effects of COVID-19 highlighting the role of the stimulation of the RAS "alternative" protective arm in attenuating pulmonary, cerebral and cardiovascular damages. In conclusion, only two clinical trials are running for Mas receptor agonists but few other molecules are in preclinical phase and if successful these drugs might represent a successful strategy for the treatment of the acute phase of COVID-19 infection.

Identifiants

pubmed: 37775018
pii: S0014-2999(23)00573-3
doi: 10.1016/j.ejphar.2023.176061
pii:
doi:

Substances chimiques

Peptidyl-Dipeptidase A EC 3.4.15.1
Angiotensin-Converting Enzyme 2 EC 3.4.17.23
Receptor, Angiotensin, Type 1 0
Anti-Inflammatory Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

176061

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The co-authors that worked to write this manuscript entitled “From cardiovascular system to brain, the potential protective role of Mas Receptors in COVID-19 infection” do not have any conflict of interests to declare.

Auteurs

Pamela Cappelletti (P)

Department of Neuro-Rehabilitation Sciences, Casa di Cura Igea, Milan, Italy. Electronic address: p.cappelletti@casadicuraigea.it.

Giovanna Gallo (G)

Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.

Rachele Marino (R)

European Brain Research Institute (EBRI) Rita Levi Montalcini Foundation, Rome, Italy.

Sakthimala Palaniappan (S)

European Brain Research Institute (EBRI) Rita Levi Montalcini Foundation, Rome, Italy.

Massimo Corbo (M)

Department of Neuro-Rehabilitation Sciences, Casa di Cura Igea, Milan, Italy.

Carmine Savoia (C)

Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.

Marco Feligioni (M)

Department of Neuro-Rehabilitation Sciences, Casa di Cura Igea, Milan, Italy; European Brain Research Institute (EBRI) Rita Levi Montalcini Foundation, Rome, Italy. Electronic address: m.feligioni@ebri.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH